181 S Franklin Ave, 4th Floor Valley Stream, NY 11581 24 Hours a Day, 7 Days a Week
The Stile Newsletter - Issue #933
Past Editions
Subject:  03.13.2026 The Stile Newsletter Issue #933

The Stile Newsletter Issue # 933 .

ISSUE #933 - 03/13/2026


Please visit us at

www.stileintl.com 

for all your import needs:

  • Tracking your shipments
  • printing documents
  • viewing your entries
  • past & present editions of the Stile Newsletter

If you need any assistance with Username and/or Password,

please contact:

williamortiz@stileintl.com

Executive Vice President



jmenendez@stileintl.com

Director of IT and Management


Extension of Import Restrictions Imposed on Certain Archaeological and Ecclesiastical Ethnological Material of Colombia - Federal Register


AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.


ACTION: Final rule.


SUMMARY: This document amends U.S. Customs and Border Protection (CBP) regulations to reflect an extension of import restrictions on certain categories of archaeological and ecclesiastical ethnological material of the Republic of Colombia, which were originally imposed in CBP Decision 06-09 and last extended by CBP Decision 21-05. The CBP regulations are being amended to reflect this extension through March 10, 2031.


DATES: Effective on March 10, 2026.


FOR FURTHER INFORMATION CONTACT: For legal aspects, W. Richmond Beevers, Chief, Cargo Security, Carriers and Restricted Merchandise Branch, Regulations and Rulings, Office of Trade, (202) 325-0084, ot-otrrculturalproperty@cbp.dhs.gov

For operational aspects, Christopher Mabelitini, Director, Intellectual Property Rights Policy & Programs, Trade Programs Directorate, Office of Trade, (571) 296-1269, 1USGBranch@cbp.dhs.gov.



SUPPLEMENTARY INFORMATION:




USITC Makes Determinations in Five-Year (Sunset) Reviews Concerning Polyethylene Terephthalate (PET) Film, Sheet, and Strip from China, India, Taiwan, and United Arab Emirates - USITC



The U.S. International Trade Commission (Commission or USITC) today determined that revoking the existing antidumping duty orders on polyethylene terephthalate (PET) film, sheet, and strip from China, India, Taiwan, and United Arab Emirates and the existing countervailing duty order on PET film, sheet, and strip from India would likely lead to continuation or recurrence of material injury within a reasonably foreseeable time. 

As a result of the Commission’s affirmative determinations, the existing orders on imports of this product from China, United Arab Emirates, India and Taiwan will remain in place. 

Chair Amy A. Karpel and Commissioners David S. Johanson and Jason E. Kearns voted in the affirmative. 

Today’s action comes under the five-year (sunset) review process required by the Uruguay Round Agreements Act. See the attached page for background on these five-year (sunset) reviews.

The Commission’s public report, Polyethylene Terephthalate Film, Sheet, and Strip from China, India, Taiwan, and United Arab Emirates (Inv. Nos. 731-TA-1132 and 1134 (Third Review) and 701-TA-415 and 731-TA-933-934 (Fourth Review), USITC Publication 5718, March 2026), will contain the views of the Commission and information developed during the reviews.

The report will be available by April 20, 2026; when available, it may be accessed on the USITC website.


BACKGROUND

The Uruguay Round Agreements Act requires the Department of Commerce to revoke an antidumping or countervailing duty order, or terminate a suspension agreement, after five years unless the Department of Commerce and the USITC determine that revoking the order or terminating the suspension agreement would be likely to lead to continuation or recurrence of dumping or subsidies (Commerce) and of material injury (USITC) within a reasonably foreseeable time. 

The Commission’s institution notice in five-year reviews requests that interested parties file responses with the Commission concerning the likely effects of revoking the order under review as well as other information. Generally, within 95 days from institution, the Commission will determine whether the responses it has received reflect an adequate or inadequate level of interest in a full review. If responses to the USITC’s notice of institution are adequate, or if other circumstances warrant a full review, the Commission conducts a full review, which includes a public hearing and issuance of questionnaires.

The Commission generally does not hold a hearing or conduct further investigative activities in expedited reviews. Commissioners base their injury determination in expedited reviews on the facts available, including the Commission’s prior injury and review determinations, responses received to its notice of institution, data collected by staff in connection with the reviews, and information provided by the Department of Commerce.

The five-year (sunset) reviews concerning polyethylene terephthalate film, sheet, and strip from China, United Arab Emirates, India, and Taiwan were instituted on August 1, 2025.

On December 22, 2025, the Commission determined to conduct expedited five-year reviews. Chair Amy A. Karpel and Commissioners David S. Johanson and Jason E. Kearns concluded that the domestic interested party group responses were adequate and the respondent interested party group responses were inadequate, and voted for expedited reviews for China, India, Taiwan, and United Arab Emirates.

A record of the Commission’s votes to conduct expedited reviews is available on the investigations pages for Polyethylene Terephthalate Film, Sheet, and Strip from China, India, Taiwan, and United Arab Emirates; Inv. Nos. 731-TA-1132 and 1134 (Third Review) and 701-TA-415 and 731-TA-933–934 (Fourth Review).



Federal Register Notices: 





CBP officers seize 214 pounds of cocaine concealed under a cargo vessel arriving in San Juan, Puerto Rico - U.S. Customs & Border Protection



SAN JUAN, Puerto Rico — U.S. Customs and Border Protection officers seized approximately 214 pounds (97 kilograms) of cocaine concealed from under a vessel arriving on Feb. 26. The estimated value of the seized cocaine is $1.7 million.

CBP officers discovered the narcotics concealed within a parasitic device attached to the hull of the M/V MEDSTAR, which arrived from Rio Haina, Dominican Republic.

The seizure occurred during a routine vessel boarding, when officers deployed underwater drone technology to inspect the vessel’s hull.

“This seizure demonstrates the dedication and skill of our officers in utilizing advanced technology to protect our borders,” said Roberto Vaquero, director of field operations in Puerto Rico and the U.S. Virgin Islands. “Our continued collaboration with local and federal partners is crucial in disrupting the flow of illicit narcotics and safeguarding our communities.”

The San Juan Municipal Police Dive Unit assisted in recovering the device from the vessel. Homeland Security Investigations responded to support the operation.

The seized cocaine was transported for further examination and secured according to established procedures.

The investigation is ongoing.





FDA Launches New Adverse Event Look-Up Tool - Food & Drug Administration



The U.S. Food and Drug Administration today launched a new unified platform for analyzing adverse event reports. This platform — called the FDA Adverse Event Monitoring System (AEMS) — represents a major achievement in the agency’s mission to modernize and provide radical transparency into the safety of regulated products. 

“The FDA’s previous adverse event reporting systems were outdated and fragmented and made important data difficult to access. These clunky systems also wasted millions of taxpayer dollars and created blind spots in our postmarket surveillance of products ranging from drugs and vaccines to cosmetics,” said FDA Commissioner Marty Makary, M.D., M.P.H. “We’re fixing the problem through a major modernization initiative. Starting today, the FDA will have a single, intuitive adverse event platform that will better serve agency scientists, researchers, and the public.”

With the new system, adverse event reports submitted to the FDA for drugs, biologics, vaccines, cosmetics, and animal food can be displayed in a single streamlined dashboard. In the months ahead, all remaining product centers will begin processing adverse event reports in AEMS. The agency will also migrate historical adverse event data to AEMS, decommission certain legacy systems, and roll out enhanced application program interfaces (APIs) and data analytics tools. By the end of May 2026, AEMS will contain real-time adverse event reports for all FDA-regulated products, consistent with meeting agency obligations not to release individually identifiable patient or consumer information.

In the past, the agency processed approximately 6 million adverse event reports per year across a patchwork of seven databases, which were expensive and had a poor user interface, making searches difficult. These platforms collectively cost the agency approximately $37 million per year to operate. Given the efficiencies of AEMS, the agency expects to save approximately $120 million over the next five years. The agency also expects the new searchable system to significantly reduce agency FOIA requests for unreleased adverse event reports, given that AEMS will publish reports in real time, rather than quarterly. 

Transparency around adverse event reports submitted by patients, consumers, clinicians and manufacturers is a critical component of the FDA’s postmarket surveillance capability. Although these reports have limitations, they can help identify potential safety signals, such as patterns or clusters of adverse events that might indicate previously unknown risks. However, the utility of these reports has often been undermined by the agency’s inefficient infrastructure. 

“Consolidating the FDA’s adverse event systems and converting to real-time publication was challenging, but made possible by a highly aggressive schedule,” said Chief AI Officer Jeremy Walsh. “The team executed with perfection and delivered the biggest technical transformation in agency history. This is the new FDA.” 



Legacy systems to be replaced by AEMS now include: 

  • FAERS (FDA Adverse Event Reporting System) — containing reports for drugs, biologics, cosmetic products, and color additives. 
  •  
  • VAERS (Vaccine Adverse Event Reporting System) — containing reports for vaccines. Note: The FDA will display VAERS data in AEMS. VAERS is co-managed by the FDA and Centers for Disease Control and Prevention. 
  •  
  • AERS (Adverse Event Reporting System) — two databases containing reports for animal drugs and animal foods. 

Legacy systems to be replaced by AEMS in May include:

  • MAUDE (Manufacturer and User Facility Device Experience) — containing reports for medical devices.
  •  
  • HFCS (Human Foods Complaint System) — containing reports for human foods and dietary supplements. 
  •  
  • TPAE (Center for Tobacco Products Adverse Event Reporting System) — containing reports for Electronic Nicotine Delivery Systems (ENDS) and other tobacco products












 
 

Stay Informed – Get the Latest Updates Straight to Your Inbox!

Sign up for our newsletter and never miss important news like our latest Special Notices, Tariff Updates, and Industry Alerts.

Simply fill out the form and get instant access to timely updates and valuable information.

Got Questions? Let’s Talk

Our experienced teams prioritize your needs, delivering solutions swiftly and professionally. We believe in blending today’s needs with tomorrow’s technology at competitive prices, ensuring your satisfaction with every shipment. At Stile Associates, we don’t just move your cargo; we move your business forward. Contact us for questions and concerns about our services. .


FacebookTwitterInstagram
Learn more about our freight forwarding company